Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma

Conditions:   Cancer;   Cancer, Lung;   Cancer of Lung;   Mesothelioma;   Mesothelioma; Lung;   Mesothelioma; Pleura;   Mesotheliomas Pleural Interventions:   Biological: UV1 vaccine + leukine;   Biological: ipilimumab;   Biological: nivolumab Sponsors:   Åslaug Helland;   Oslo University Hospital;   Ultimovacs ASA;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials